ArticleJournal of virology2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Review
- Progress and prospects on vaccine development against monkeypox infection.Microbial pathogenesis · 2023Review
- Article
- Fengreqing Oral Liquid Exerts Anti-Inflammatory Effects by Promoting Apoptosis and Inhibiting PI3K/AKT and NF-κB Signaling Pathways.Frontiers in pharmacology · 2022Article
- Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study.Frontiers in immunology · 2022Article
- Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YbioRxiv : the preprint server for biology · 2021Article
- Article
- Modified Vaccinia Virus Ankara Can Induce Optimal CD8Journal of virology · 2019Article
- Review
- Article
- Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.Journal of virology · 2019Article
- Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.Journal of virology · 2019Article
- Apoptosis and apoptotic body: disease message and therapeutic target potentials.Bioscience reports · 2019Review
- CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.Frontiers in cell and developmental biology · 2019Review
- AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.Viruses · 2018Review
- Passive and active antibody studies in primates to inform HIV vaccines.Expert review of vaccines · 2018Review
- Review
- Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 16 institutions in 5 countries.
Juan García-ArriazaDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Beatriz PerdigueroDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Jonathan L HeeneyDepartment of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
David C MontefioriDuke University Medical Center, Durham, North Carolina, USA.
Nicole L YatesDuke University Medical Center, Durham, North Carolina, USA.
Georgia D TomarasDuke University Medical Center, Durham, North Carolina, USA.
Guido FerrariDuke University Medical Center, Durham, North Carolina, USA.
Kathryn E FouldsVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Steven G SelfStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Bhavesh BorateStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Raphael GottardoStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Sanjay PhogatSanofi Pasteur, Swiftwater, Pennsylvania, USA.
Jim TartagliaSanofi Pasteur, Swiftwater, Pennsylvania, USA.
Susan W BarnettNovartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA.
Brian BurkeNovartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA.
Anthony D CristilloAdvanced BioScience Laboratories, Inc., Rockville, Maryland, USA.
Deborah E WeissAdvanced BioScience Laboratories, Inc., Rockville, Maryland, USA.
Carter LeeGlobal Solutions on Infectious Diseases, South San Francisco, California, USA.
Karen V KiblerBiodesign Institute, Arizona State University, Tempe, Arizona, USA.
Bertram L JacobsBiodesign Institute, Arizona State University, Tempe, Arizona, USA.
Ralf WagnerUniversity of Regensburg, Regensburg, Germany.
Song DingEuroVacc Foundation, Lausanne, Switzerland.
Giuseppe PantaleoDivision of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Mariano EstebanDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain mesteban@cnb.csic.es.
Duke Medical Center · USFred Hutch Cancer Center · USAdvanced Bioscience Laboratories (United States) · USArizona State University · USCentro Nacional de Biotecnología · ESNovartis (United States) · USSanofi (United States) · USBeth Israel Deaconess Medical Center · USConsejo Superior de Investigaciones Científicas · ESEurovacc Foundation · CHGlobal Solutions for Infectious Diseases · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USUniversity Hospital of Lausanne · CHUniversity of Cambridge · GBUniversity of Regensburg · DE
Funding
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MNIAID NIH HHS HHSN266200500030CNIAID NIH HHS P30 AI064518
Abstract
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C(CN54) HIV-1 Env(gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in phase I clinical trials. To enhance the capacity of the NYVAC vector to trigger broad humoral responses and a more balanced activation of CD4
Indexed as
AIDS VaccinesAnimalsAntibodies, NeutralizingAntibody-Dependent Cell CytotoxicityCD4-Positive T-LymphocytesCD8-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV AntigensHIV Envelope Protein gp120HIV InfectionsInterferon Type IMacaca mulattaMaleReceptors, InterferonVaccinationAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV AntigensHIV Envelope Protein gp120Interferon Type INYVAC-C vaccineReceptors, InterferonVaccines, Virus-Like ParticleB19Rcellular responsesHIV-1humoral responsesimmunogenicitynonhuman primatesNYVACpoxvirus
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.